Sgambato-Faure Véronique, Billard Thierry, Météreau Elise, Duperrier Sandra, Fieux Sylvain, Costes Nicolas, Tremblay Léon, Zimmer Luc
Université Claude Bernard Lyon ILyon, France.
Institut des Sciences Cognitives Marc Jeannerod, CNRS UMR5229Bron, France.
Front Pharmacol. 2017 Jul 18;8:471. doi: 10.3389/fphar.2017.00471. eCollection 2017.
Brain serotonin-6 receptor (5-HTR) is the one of the most recently identified serotonin receptors. Accumulating evidence suggests that it is a potent therapeutic target for psychiatric and neurological diseases. Since [F]2FNQ1P was recently proposed as the first fluorinated positron emission tomography (PET) radioligand for this receptor, the objective of the present study was to demonstrate its suitability for 5-HTR neuroimaging in primates. [F]2FNQ1P was characterized by autoradiography and PET imaging in cynomolgus monkeys. Following PET imaging, tracer binding indices were computed using the simplified reference tissue model and Logan graphical model, with cerebellum as reference region. The tracer binding reproducibility was assessed by test-retest in five animals. Finally, specificity was assessed by pre-injection of a 5-HTR antagonist, SB258585. results showed wide cerebral distribution of the tracer with specificity toward 5-HTRs as binding was effectively displaced by SB258585. brain penetration was good with reproducible distribution at cortical and subcortical levels. The automated method gave the best spatial normalization. The Logan graphical model showed the best tracer binding indices, giving the highest magnitude, lowest standard deviation and best reproducibility and robustness. Finally, 5-HTR antagonist pre-injection significantly decreased [F]2FNQ1P binding mainly in the striatum and sensorimotor cortex. Taken together, these preclinical results show that [F]2FNQ1P is a good candidate to address 5-HT6 receptors in clinical studies.
脑血清素-6受体(5-HTR)是最近发现的血清素受体之一。越来越多的证据表明,它是治疗精神疾病和神经疾病的有效靶点。由于[F]2FNQ1P最近被提议作为该受体的首个氟化正电子发射断层扫描(PET)放射性配体,本研究的目的是证明其适用于灵长类动物的5-HTR神经成像。通过食蟹猴的放射自显影和PET成像对[F]2FNQ1P进行了表征。PET成像后,使用简化参考组织模型和洛根图形模型,以小脑为参考区域计算示踪剂结合指数。通过对五只动物进行重测评估示踪剂结合的重现性。最后,通过预先注射5-HTR拮抗剂SB258585评估特异性。结果显示,该示踪剂在脑内分布广泛,对5-HTR具有特异性,因为SB258585有效地取代了结合。脑渗透性良好,在皮质和皮质下水平分布具有可重复性。自动方法给出了最佳的空间归一化。洛根图形模型显示了最佳的示踪剂结合指数,幅度最高、标准差最低、重现性和稳健性最佳。最后,预先注射5-HTR拮抗剂主要使纹状体和感觉运动皮层的[F]2FNQ1P结合显著降低。综上所述,这些临床前结果表明,[F]2FNQ1P是临床研究中针对5-HT6受体的良好候选物。